Periodic Reporting for period 1 - NanoSil4Cancer (Smart Multifunctional silica-based Nanoparticles for Targeted Therapy)
Reporting period: 2016-09-01 to 2017-02-28
NanoSil4Cancer is an innovative biocompatible device able to administer cancer therapies with low drug doses, high therapeutic efficacy and reduced side effects. Therapeutic efficacy increases because drugs are directly administered to cancer cells. NanoSiliCal reformulates known, approved drugs, through its proprietary drug delivery technology and creates new medications with improved clinical and economic benefits for patients and healthcare stakeholders.
The objectives for the Phase I study included (1) the analysis of customer needs, (2) analysis of the market size, (3) partner search and B2B strategy development, (4) the refinement of the business model and go-to-market strategy, (5) risk assessment, (6) elaboration of a long term perspective financial plan.
The epidemiological analysis provides evidence of the growth of cancer incidence and the need of treatments of higher efficacy and safety.
The economic impact of NanoSiliCal MSN prototypes development, analyzed on the base of financial projections, shows a highly competitive formulation development cost structure.
Several other drugs presenting features compatible with MSN have been identified, for developing NanoSilical pipeline.
Industrial stakeholders helped NanoSilical to define the company strategic plan to obtain marketing authorization and market penetration.
After the clinical trial stage, two different possible scenarios are foreseen, depending on the business agreement with present and possible future investors/partners : or the direct marketing of the product, or exclusive license of the prototype to a pharmaceutical company.
NanoSil4Cancer addresses cancer patient needs, developing an innovative technology for targeted drug delivery systems that can reduce side effects, thus increasing patients quality of life.